

**INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED
DURING THE FIRST HALF OF 2024
OF SOPHARMA GROUP**

Annex № 4

**To Art. 12, par. 1, it.1, art.14 of Ordinance № 2 from 09.11.2021
And Regulation (EU) 596/2014 of the European Parliament and of the Council
of April 16, 2014**

The persons who are liable for damages caused by false, misleading or incomplete data in this information as of June 30, 2024 are:

*Ognyan Donev - Executive Director and Chairman of the Board of Directors of Sopharma AD
Vesela Stoeva – Deputy- Chairman of the Board of Directors of Sopharma AD
Bisera Lazarova – Member of the Board of Directors of Sopharma AD
Alexander Tchaushev – Member of the Board of Directors of Sopharma AD
Ivan Badinski - Member of the Board of Directors of Sopharma AD*

- 1.1. No change in the persons controlling the Company.
- 1.2. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.3. No conclusion or execution of significant transactions.
- 1.4. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.5. Change of the auditors of the company - No change of auditors.
- 1.6. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.
- 1.7. On 21.02.2024, through its subsidiary Sopharmacy EOOD, the Group acquired the companies Sopharmacy 66 EOOD, Sopharmacy 67 EOOD and Sopharmacy 68 EOOD. On 13.03.2024, through its subsidiary Sopharmacy EOOD, the Group acquired the company Sopharmacy 65 EOOD.
- 1.8. The management believes that the military conflict between Russia and Ukraine could have a serious impact on the Company's activities, since the main part of product sales are realized in Ukraine and Russia.

The company has investments in two subsidiaries in Ukraine. As of the date of preparation of the financial statements, the assets of these subsidiaries are not physically affected by military action, but it is possible that in the future the value of these investments may need to be reviewed depending on the development of the war and its impact on the activities of the companies.

Information under Art. 12, para. 1, item 2 of REGULATION No. 2 of November 11, 2021 on initial and subsequent disclosure of information during public offering of securities and admission of securities to trading on a regulated market.

Electronic reference to the place on the website of the public company, where the internal information under Art. 7 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Directives 2003 /124/EC, 2003/125/EC and 2004/72/EC of the Commission (OB, L 173/1 of June 12, 2014) (Regulation (EU) No 596/2014) regarding the circumstances that occurred in the first half of 2024, or an electronic reference to the issuer's chosen news agency or other media through which the company makes public the inside information:

In the period January 1, 2024 – June 30, 2024, Sopharma AD discloses information to the Financial Supervision Agency, Bulgarian Stock Exchange, Warsaw Stock Exchange and the public,

*This is a translation from Bulgarian of the Consolidated financial statements
of Sopharma Group.*

In case of divergence Bulgarian text should prevail.

through the information platform x3news (<http://www.x3news.com>), through the corporate page of the company in the "Investors" section (<https://www.sopharmagroup.com/bg/investitori>), on the investor.bg information site (<https://www.investor.bg/bulletin>) and on the Infostrefa (<https://infostrefa.com/infostrefa/pl/profil/845>, SOPHARMA).

"Sopharma" AD informs all interested parties that the consolidated financial statements of the Company as of June 30, 2024 have not been verified by a registered auditor.